Cat. # | Size | Price | Inventory |
---|---|---|---|
9870T | 1 Kit (8 x 20 microliters) |
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
Phospho-cdc2 (Tyr15) (10A11) Rabbit mAb 4539 | 20 µl |
|
H M R Mk | 34 | Rabbit |
Cyclin A2 (BF683) Mouse mAb 4656 | 20 µl |
|
H | 55 | Mouse IgE |
Cyclin B1 (D5C10) XP® Rabbit mAb 12231 | 20 µl |
|
H R | 55 | Rabbit IgG |
Cyclin E2 Antibody 4132 | 20 µl |
|
H | 48 | Rabbit |
Phospho-Histone H3 (Ser10) (D2C8) XP® Rabbit mAb 3377 | 20 µl |
|
H M R Mk Z | 17 | Rabbit IgG |
Myt1 Antibody 4282 | 20 µl |
|
H M R | 60 to 70 | Rabbit |
p21 Waf1/Cip1 (12D1) Rabbit mAb 2947 | 20 µl |
|
H Mk | 21 | Rabbit IgG |
Phospho-Wee1 (Ser642) (D47G5) Rabbit mAb 4910 | 20 µl |
|
H | 95 | Rabbit IgG |
Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Goat | ||
Anti-mouse IgG, HRP-linked Antibody 7076 | 100 µl |
|
Horse |
Product Information
Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues near the carboxy-terminus of human cyclin E2 or the middle of mouse and human Myt1. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibody is produced by immunizing animals with synthetic peptides corresponding to residues near the carboxy-terminus of human p21, residues near the amino terminus of human cyclin B1 protein, or recombinant human cyclin A2 protein. Activation state monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Ser10 of human histone H3, residues surrounding Ser642 of human Wee1, or residues surrounding Tyr15 of human cdc2.
The critical regulatory step in activating cdc2 during progression into mitosis appears to be dephosphorylation of cdc2 at Tyr15 and Thr14 (1). Phosphorylation of cdc2 by the protein kinases Wee1 and Myt1 at Thr14 and Tyr15 results in inhibition of cdc2 (2,3). Progression through the G1/S checkpoint and initiation of DNA replication requires cyclin E; traversing the G2/M checkpoint to initiate mitosis requires cyclin B, and cyclin A may be required for both S-phase and M-phase (4). The versatile p21 cyclin-dependent kinase inhibitor, which interacts with several cyclin-CDK complexes to regulate cyclin-CDK during the cell cycle, is regulated by phosphorylation and ubiquitin-mediated degradation (5). Phosphorylation of histone H3 at Ser10 and neighboring residues correlates with chromosomal condensation, which is essential for segregation of chromosomes during mitosis (6).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.